ITM Gets FDA Complete Response for ITM-11 Over Manufacturing Issues

The U.S. Food and Drug Administration issued an FDA complete response letter to ITM for its radiopharmaceutical candidate, citing only manufacturing and facility inspection issues as obstacles to approval. Clinical data, nonclinical studies, and the established safety profile needed no further revision or additional submissions.

FDA Complete Response Letter Focuses on Manufacturing

The regulatory communication from the U.S. Food and Drug Administration highlights manufacturing and facility inspection matters as the sole barriers to approval of the radiopharmaceutical agent under review. Clinical and nonclinical elements of the submission, including the established safety profile, require no further data or revision. The sponsor intends to resolve the identified items through engagement with external partners and to resubmit the application without altering its underlying therapeutic rationale. This targeted approach preserves the original development strategy while addressing the specific Chemistry, Manufacturing and Controls deficiencies noted in the FDA complete response letter.

Pivotal Trial Demonstrates Clear Efficacy Advantage

The pivotal evaluation employed a randomized comparison of the investigational radiotherapeutic against everolimus in patients with progressive, inoperable gastroenteropancreatic neuroendocrine tumors graded 1 or 2. Progression-free survival served as the primary endpoint, with the trial design confirming both statistical and clinical superiority for the radiopharmaceutical arm. Supporting evidence derives from this completed Phase 3 study, which forms the unchanged data foundation referenced in the regulatory response. Absence of any clinical objections in the FDA complete response letter isolates Chemistry, Manufacturing and Controls deficiencies and third-party site inspection outcomes as the exclusive review impediments. The trial results demonstrated a meaningful extension in progression-free survival relative to the molecular comparator, thereby preserving the product’s efficacy narrative.

Ongoing assessment of the feedback focuses on remediation timelines rather than any reevaluation of patient-level outcomes or tolerability data. Resolution of the Chemistry, Manufacturing and Controls and facility-related items will determine the interval before resubmission and subsequent market availability for patients with advanced gastroenteropancreatic neuroendocrine tumors. The sponsor’s maintained confidence in the existing evidence package suggests that targeted manufacturing adjustments can restore the application’s review trajectory without additional clinical investment. For health economics and outcomes research planning, this sequence underscores the need to model potential delays in access while the core progression-free survival advantage remains intact for future reimbursement positioning. Industry observers note that similar FDA complete response letter scenarios in radiopharmaceutical development have been resolved within 12 to 18 months when sponsors collaborate closely with contract manufacturing organizations.